Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY G SOMER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1851320691
CMS profile
219649
Location
GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$33,351.20

62 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY G SOMER

NPI 1851320691 · CMS profile ID 219649

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GERMANTOWN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851320691?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY G SOMER, NPI 1851320691, CMS profile ID 219649. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851320691?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRADLEY G SOMER, NPI 1851320691, CMS profile ID 219649. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851320691?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRADLEY G SOMER, NPI 1851320691, CMS profile ID 219649, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1851320691?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

62 matching records · $33,351.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 62 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–62 of 62.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $817.5003/28/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988761407 CMS
E.R. Squibb & Sons, L.L.C. $15.7703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015817215 CMS
E.R. Squibb & Sons, L.L.C. $16.3303/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015817223 CMS
AstraZeneca Pharmaceuticals LP $250.0002/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015419409 CMS
AstraZeneca Pharmaceuticals LP $250.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014826739 CMS
AstraZeneca Pharmaceuticals LP $250.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015645581 CMS
Novartis Pharmaceuticals Corporation $16.2402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993382021 CMS
Seagen Inc. $10.2902/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995636299 CMS
Merck Sharp & Dohme LLC $41.4801/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048657987 CMS
Coherus Biosciences Inc. $14.3201/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060237257 CMS
PFIZER INC. $13.5401/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050581313 CMS
Sumitomo Pharma America, Inc. $21.3001/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030756121 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,811.70 64
PY2020 $18,595.54 28
PY2021 $7,377.52 40
PY2022 $11,720.42 58
PY2023 $33,351.20 62
PY2024 $33,057.33 70
PY2025 $53,067.53 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $520,883.39 46
PY2024 Principal investigator $750,330.42 75
PY2023 Principal investigator $733,470.19 23
PY2022 Principal investigator $538,638.95 43
PY2021 Principal investigator $398,741.21 59
PY2020 Principal investigator $260,292.96 59
PY2019 Principal investigator $864,934.10 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,628.12 12/31/2025 Non-covered Recipient Entity
The West Clinic, PLLC dba West Cancer Center
A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinoma, Gastroesophageal Junction Adenoca No dispute reported 06/30/2026 1232924242
Principal investigator 1 Merck Sharp & Dohme LLC $11,480.99 12/31/2025 Non-covered Recipient Entity
The West Clinic, P.C.
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE No dispute reported 06/30/2026 1232926307
Principal investigator 1 Merck Sharp & Dohme LLC $19,689.04 12/31/2025 Non-covered Recipient Entity
The West Clinic, PLLC dba West Cancer Center
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor No dispute reported 06/30/2026 1232930053
Principal investigator 1 Merck Sharp & Dohme LLC $11,014.20 12/31/2025 Non-covered Recipient Entity
The West Clinic, PLLC dba West Cancer Center
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232935407
Principal investigator 1 PFIZER INC. $197.60 12/18/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228749677
Principal investigator 1 Genentech, Inc. $10,750.00 12/16/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211671745
Principal investigator 1 Genentech, Inc. $1,000.00 12/16/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211671748
Principal investigator 1 Genentech, Inc. $1,000.00 12/16/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211671754
Principal investigator 1 Genentech, Inc. $354.00 12/16/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211671759
Principal investigator 1 Genentech, Inc. $1,500.00 12/16/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211671764
Principal investigator 1 Genentech, Inc. $1,006.00 11/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211671722
Principal investigator 1 Merck Sharp & Dohme LLC $20,818.55 11/19/2025 Non-covered Recipient Entity
The West Clinic, PLLC dba West Cancer Center
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232935405
Principal investigator 1 PFIZER INC. $17,720.00 11/14/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228714847
Principal investigator 1 PFIZER INC. $197.60 10/21/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228742991
Principal investigator 1 Merck Sharp & Dohme LLC $2,668.00 10/17/2025 Non-covered Recipient Entity
The West Clinic, P.C.
A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE No dispute reported 06/30/2026 1232926305
Principal investigator 1 Merck Sharp & Dohme LLC $99,585.60 08/31/2025 Non-covered Recipient Entity
The West Clinic, PLLC dba West Cancer Center
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232935409
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,117.00 07/23/2025 Non-covered Recipient Entity
WEST CANCER CENTER
Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer No dispute reported 06/30/2026 1185545669
Principal investigator 1 PFIZER INC. $9,935.10 07/16/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228783399
Principal investigator 1 PFIZER INC. $8,860.00 06/26/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228778285
Principal investigator 1 Amgen Inc. $6,400.00 06/25/2025 Non-covered Recipient Entity
WEST CLINIC PC
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246652081
Principal investigator 1 AstraZeneca UK Limited $5,831.57 06/09/2025 Non-covered Recipient Entity
WEST CANCER CENTER AND RESEARCH INSTITUTE
ROSY-D Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment No dispute reported 06/30/2026 1185545667
Principal investigator 1 PFIZER INC. $830.70 05/14/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228764697
Principal investigator 1 AstraZeneca UK Limited $6,500.00 05/08/2025 Non-covered Recipient Entity
WEST CANCER CENTER
ROSY-D Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment No dispute reported 06/30/2026 1185545663
Principal investigator 1 PFIZER INC. $8,860.00 05/01/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228772326
Principal investigator 1 Ipsen Bioscience Inc. $750.00 04/25/2025 Non-covered Recipient Entity
West Clinic Pharmacy
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176545937
Principal investigator 1 PFIZER INC. $8,850.00 04/19/2025 Non-covered Recipient Entity
The West Clinic PLLC
A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600EMUTANT MSI HDMMR METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228794364
Principal investigator 1 PFIZER INC. $418.60 04/16/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228779351
Principal investigator 1 PFIZER INC. $96.00 04/07/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228759592
Principal investigator 1 PFIZER INC. $90.00 04/07/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228761182
Principal investigator 1 PFIZER INC. $160.00 04/07/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228769541
Principal investigator 1 PFIZER INC. $1,249.30 03/28/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228787523
Principal investigator 1 Genentech, Inc. $551.00 03/20/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211671590
Principal investigator 1 PFIZER INC. $14,721.60 03/17/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228770118
Principal investigator 1 PFIZER INC. $9,690.70 03/14/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228794244
Principal investigator 1 PFIZER INC. $54.72 02/24/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228769290
Principal investigator 1 PFIZER INC. $160.00 02/24/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228769596
Principal investigator 1 Amgen Inc. $9,309.00 02/21/2025 Non-covered Recipient Entity
WEST CANCER CENTER
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression No dispute reported 06/30/2026 1246652077
Principal investigator 1 PFIZER INC. $1,249.30 02/14/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228769948
Principal investigator 1 PFIZER INC. $7,360.80 02/10/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228769285
Principal investigator 1 Genentech, Inc. $3,763.00 02/04/2025 Non-covered Recipient Entity
THE WEST CLINIC PC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211671586
Principal investigator 1 PFIZER INC. $54.72 01/27/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228761091
Principal investigator 1 PFIZER INC. $418.60 01/25/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228720063
Principal investigator 1 AstraZeneca Pharmaceuticals LP $207,482.68 01/24/2025 Non-covered Recipient Entity
WEST CANCER CENTER
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185545665
Principal investigator 1 PFIZER INC. $80.00 01/15/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228769591
Principal investigator 1 PFIZER INC. $1,249.30 01/15/2025 Non-covered Recipient Entity
West Clinic Research Department
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228798715
Principal investigator 1 PFIZER INC. $180.00 01/14/2025 Non-covered Recipient Entity
TheWestClinicWestCancerCenter
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228720205